Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
ArriVent BioPharma, Inc. ( (AVBP) ) just unveiled an announcement.
On March 17, 2026, ArriVent BioPharma announced it would present new preclinical data on its EGFR inhibitor firmonertinib and dual-target MUC16/NaPi2b tetravalent ADC ARR-002 at the 2026 American Association for Cancer Research Annual Meeting in San Diego, running April 17-22. The firmonertinib poster is set to showcase high-resolution structural and functional data supporting its pivotal Phase 3 programs in EGFR exon 20 insertion and PACC mutant non-small cell lung cancer, while ARR-002 data with partner Aarvik Therapeutics will highlight superior anti-tumor activity, enhanced internalization and a favorable tolerability profile in ovarian and endometrial cancer models, reinforcing ArriVent’s push to position its assets as next-generation targeted oncology therapies.
For firmonertinib, preclinical work demonstrated high-potency inhibition across classical and exon 20 insertion EGFR mutations, strong brain penetration and robust anti-tumor activity in multiple in vitro and in vivo models, supporting its role in global late-stage trials. ARR-002, a first-in-class dual-target tetravalent ADC discovered with Aarvik and licensed by ArriVent, showed effective engagement of both MUC16 and NaPi2b, superior in vivo efficacy versus single-target ADCs and signs of a wider therapeutic window in primate studies, suggesting best-in-disease potential in ovarian and endometrial cancers and underlining ArriVent’s broader strategy to build a competitive ADC-based oncology franchise.
The most recent analyst rating on (AVBP) stock is a Buy with a $42.00 price target. To see the full list of analyst forecasts on ArriVent BioPharma, Inc. stock, see the AVBP Stock Forecast page.
Spark’s Take on AVBP Stock
According to Spark, TipRanks’ AI Analyst, AVBP is a Neutral.
The score is primarily driven by a strong, low-leverage balance sheet, offset by accelerating losses and cash burn with no revenue yet. Technicals add modest support due to an uptrend versus moving averages and positive MACD, while valuation remains pressured by negative earnings and no dividend.
To see Spark’s full report on AVBP stock, click here.
More about ArriVent BioPharma, Inc.
ArriVent BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing differentiated cancer medicines. The company’s lead candidate is the EGFR inhibitor firmonertinib, and it is also advancing a pipeline that includes next-generation antibody-drug conjugates such as ARR-002 for hard-to-treat tumors.
Average Trading Volume: 501,214
Technical Sentiment Signal: Strong Buy
Current Market Cap: $1.07B
Learn more about AVBP stock on TipRanks’ Stock Analysis page.